Definium Therapeutics Financials - Benzinga

Definium Therapeutics Inc

DFTXNASDAQ

Trade with Public

Trade with Public

$37.36

-0.29-0.77%

最終更新: Sep 24, 9:27 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Definium Therapeutics Financials

Definium Therapeutics (DFTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Definium Therapeutics Q2 EPS $(1.44) Misses $(0.55) Estimate

Benzinga Newsdesk

PRO
Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M

Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.48) by 47.92 percent. This is a 102.86 percent decrease over losses of $(0.35) per

Benzinga Newsdesk

PRO
Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.

Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.46) by 7.76 percent. This is a 21.95 percent decrease over losses of $(0.41) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

Earnings Preview For Definium Therapeutics

Benzinga Insights

© 2026 Benzinga | All Rights Reserved